Irinotecan pathway genotype analysis to predict pharmacokinetics

Clinical Cancer Research

Volumn 9, Issue 9, 2003, Pages 3246-3253

  Mathijssen, Ron H J ^a   Marsh, Sharon ^b   Karlsson, Mats O ^c   Xie, Rujia ^c   Baker, Sharyn D ^d   Verweij, Jaap ^a   Sparreboom, Alex ^a,e   McLeod, Howard L ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UPPSALA UNIVERSITY   (Sweden)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BREAST CANCER RESISTANCE PROTEIN; CARBOXYLESTERASE; CARBOXYLESTERASE 1; CARBOXYLESTERASE 2; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLYCOPROTEIN P; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; CONFERENCE PAPER; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ADULT; AGED; ALLELES; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; CARBOXYLESTERASE; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME SYSTEM; DNA-BINDING PROTEINS; FEMALE; GENE FREQUENCY; GENOTYPE; GLUCURONIC ACIDS; GLUCURONOSYLTRANSFERASE; HOMOZYGOTE; HUMANS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MODELS, BIOLOGICAL; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN BINDING;

EID: 0042196122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (35)

1. Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., Elfring, G. L., and Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 343: 905-914, 2000.
2. Mathijssen, R. H., van Alphen, R. J., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., and Sparreboom, A. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res., 7: 2182-2194, 2001.
3. Raymond, E., Boige, V., Faivre, S., Sanderink, G. J., Rixe, O., Vernillet, L., Jacques, C., Gatineau, M., Ducreux, M., and Armand, J. P. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J. Clin. Oncol., 20: 4303-4312, 2002.
4. Ong, S. Y., Clarke, S. J., Bishop, J., Dodds, H. M., and Rivory, L. P. Toxicity of irinotecan (CPT-11) and hepato-renal dysfunction. Anticancer Drugs, 12: 619-625, 2001.
5. Evans, W. E., and McLeod, H. L. Pharmacogenomics: drug disposition, drug targets, and side effects. N. Engl. J. Med., 348: 538-549, 2003.
6. Bencharit, S., Morton, C. L., Howard-Williams, E. L., Danks, M. K., Potter, P. M., and Redinbo, M. R. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat. Struct. Biol., 9: 337-342, 2002.
7. Hanioka, N., Ozawa, S., Jinno, H., Ando, M., Saito, Y., and Sawada, J. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica, 31: 687-699, 2001.
8. Haaz, M. C., Rivory, L., Riche, C., Vernillet, L., and Robert, J. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res., 58: 468-472, 1998.
9. Iyer, L., Ramirez, J., Shepard, D. R., Bingham, C. M., Hossfeld, D. K., Ratain, M. J., and Mayer, U. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice. Cancer Chemother. Pharmacol., 49: 336-341, 2002.
10. Chen, Z. S., Furukawa, T., Sumizawa, T., Ono, K., Ueda, K., Seto, K., and Akiyama, S. I. ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol. Pharmacol., 55: 921-928, 1999.
11. Chu, X. Y., Kato, Y., Niinuma, K., Sudo, K. I., Hakusui, H., and Sugiyama, Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J. Pharmacol. Exp. Ther., 281: 304-314, 1997.
12. Nakatomi, K., Yoshikawa, M., Oka, M., Ikegami, Y., Hayasaka, S., Sano, K., Shiozawa, K., Kawabata, S., Soda, H., Ishikawa, T., Tanabe, S., and Kohno, S. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells. Biochem. Biophys. Res. Commun., 288: 827-832, 2001.
13. Sparreboom, A., de Jonge, M. J., de Bruijn, P., Brouwer, E., Nooter, K., Loos, W. J., van Alphen, R. J., Mathijssen, R. H., Stoter, G., and Verweij, J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clin. Cancer Res., 4: 2747-2754, 1998.
14. de Bruijn, P., Verweij, J., Loos, W. J., Nooter, K., Stoter, G., and Sparreboom, A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B Biomed. Sci. Appl., 698: 277-285, 1997.
15. Xie, R., Mathijssen, R. H., Sparreboom, A., Verweij, J., and Karlsson, M. O. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis. J. Clin. Oncol., 20: 3293-3301, 2002.
16. Iyer, L., Das, S., Janisch, L., Wen, M., Ramirez, J., Karrison, T., Fleming, G. F., Vokes, E. E., Schilsky, R. L., and Ratain, M. J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J., 2: 43-47, 2002.
17. Marsh, S., Kwok, P., and McLeod, H. L. SNP databases and pharmacogenetics: great start, but a long way to go. Hum. Mutat., 20: 174-179, 2002.
18. Ameyaw, M. M., Regateiro, F., Li, T., Liu, X., Tariq, M., Mobarek, A., Thornton, N., Folayan, G, O., Githang'a, J., Indalo, A., Ofori-Adjei, D., Price-Evans, D. A., and McLeod, H. L. MDR1 pharmacogenetics: frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity. Pharmacogenetics, 11: 217-221, 2001.
19. Monaghan, G., Ryan, M., Seddon, R., Hume, R., and Burchell, B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet, 347: 578-581, 1996.
20. Ronaghi, M. Pyrosequencing sheds light on DNA sequencing. Genome Res., 11: 3-11, 2001.
21. Sham, P. C., and Curtis, D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Ann. Hum. Genet., 59: 97-105, 1995.
22. Schaid, D. J., McDonnell, S. K., Wang, L., Cunningham, J. M., and Thibodeau, S. N. Caution on pedigree haplotype inference with software that assumes linkage equilibrium. Am. J. Hum. Genet., 71: 992-995, 2002.
23. Park, S. Y., Lam, W., and Cheng, Y. C. X-ray repair cross-complementing gene I protein plays an important role in camptothecin resistance. Cancer Res., 62: 459-465, 2002.
24. Tang, K., Ngoi, S. M., Gwee, P. C., Chua, J. M., Lee, E. J., Chong, S. S., and Lee, C. G. Distinct haplotype profiles and strong linkage disequilibrium at the MDR1 multidrug transporter gene locus in three ethnic Asian populations. Pharmacogenetics, 12: 437-450, 2002.
25. Bosma, P. J., Chowdhury, J. R., Bakker, C., Gantla, S., de Boer, A., Oostra, B. A., Lindhout, D., Tytgat, G. N., Jansen, P. L., Oude Elferink, R. P., and Chowdhury, N. R. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med., 333: 1171-1175, 1995.
26. Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H. P., Brockmoller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M., and Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 97: 3473-3478, 2000.
27. Fellay, J., Marzolini, C., Meaden, E. R., Back, D. J., Buclin, T., Chave, J. P., Decosterd, L. A., Furrer, H., Opravil, M., Pantaleo, G., Retelska, D., Ruiz, L., Schinkel, A. H., Vernazza, P., Eap, C. B., and Telenti, A. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet, 359: 30-36, 2002.
28. Sparreboom, A., Danesi, R., Ando, Y., Chan, J., and Figg, W. D. Pharmacogenomics of ABC transporters and its role in cancer chemotherapy. Drug Res. Updates, 266: 71-84, 2003.
29. Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., and Chowdhury, N. R. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat., 16: 297-306, 2000.
30. Ando, Y., Saka, H., Ando, M., Sawa, T., Muro, K., Ueoka, H., Yokoyama, A., Saitoh, S., Shimokata, K., and Hasegawa, Y, Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 60: 6921-6926, 2000.
31. Gagne, J. F., Montminy, V., Belanger, P., Journault, K., Gaucher, G., and Guillemette, C. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol. Pharmacol., 62: 608-617, 2002.
32. Ritter, J. K., Kessler, F. K., Thompson, M. T., Grove, A. D., Auyeung, D. J., and Fisher, R. A. Expression and inducibility of the human bilirubin UDP-glucuronosyltransferase UGT1A1 in liver and cultured primary hepatocytes: evidence for both genetic and environmental influences. Hepatology, 30: 476-484, 1999.
33. McCune, J. S., Hawke, R. L., LeCluyse, E. L., Gillenwater, H. H., Hamilton, G., Ritchie, J., and Lindley, C. In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone. Clin. Pharmacol. Ther., 68: 356-366, 2000.
34. Kehrer, D. F., Mathijssen, R. H., Verweij, J., de Bruijn, P., and Sparreboom, A. Modulation of irinotecan metabolism by ketoconazole. J. Clin. Oncol., 20: 3122-3129, 2002.
35. Mathijssen, R. H., Verweij, J., de Bruijn, P., Loos, W. J., and Sparreboom, A. Effects of St. John's wort on irinotecan metabolism, J. Natl. Cancer Inst. (Bethesda), 94: 1247-1249, 2002.